Loading…

Clinical utility of a model‐based amoxicillin dosage regimen in neonates with early‐onset sepsis

Early‐onset sepsis (EOS) is one of the most significant causes of morbidity and mortality in neonates. Currently, amoxicillin is empirically used to treat neonates with EOS. However, data on its effectiveness in neonates with EOS are still limited. Therefore, we aimed to evaluate the pharmacodynamic...

Full description

Saved in:
Bibliographic Details
Published in:British journal of clinical pharmacology 2022-11, Vol.88 (11), p.4950-4955
Main Authors: Kou, Chen, Li, Di‐Fei, Tang, Bo‐Hao, Dong, Lei, Yao, Bu‐Fan, Anker, John, You, Dian‐Ping, Wu, Yue‐E, Zhao, Wei
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Early‐onset sepsis (EOS) is one of the most significant causes of morbidity and mortality in neonates. Currently, amoxicillin is empirically used to treat neonates with EOS. However, data on its effectiveness in neonates with EOS are still limited. Therefore, we aimed to evaluate the pharmacodynamics (PD) target attainment and effectiveness of a model‐based amoxicillin dosage regimen in these neonates. We used a previously developed model and collected additional clinical data from the EOS neonates who used the model‐based dosage regimen (25 mg/kg every 12 h). The primary outcomes were PD target attainment (free drug concentration above minimum inhibitory concentration during 70% of the dosing interval) and treatment failure rate. The secondary endpoints were length of amoxicillin treatment, duration of hospitalization etc. Seventy‐five neonates (postmenstrual age 28.4–41.6 wk) were enrolled. A total of 70 (93.3%) neonates reached their PD target using 1 mg/L as the minimum inhibitory concentration breakpoint. The treatment failure rate was 10.7%.
ISSN:0306-5251
1365-2125
DOI:10.1111/bcp.15521